Merus (MRUS) and Halozyme Therapeutics (HALO) announced they have entered into a global non-exclusive collaboration and license agreement. Under the collaboration, Merus has licensed Halozyme’s ENHANZE drug delivery technology, for the development and potential commercialization of subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody. Under the terms of the agreement, Merus will make an upfront payment to Halozyme, and potential future milestone payments related to commercial and sales attainment, if approved. Halozyme will also be entitled to up to low-mid single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Soros buys Disney, boosts Amazon in Q3
- Merus N.V. Shareholders to Vote on Genmab Acquisition Offer
- Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline
- Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities
- Merus NV Faces Uncertainty and Risks Amid Genmab A/S Transaction Delays